{"prompt": "['Product: MK-3475', '44', 'Protocol/Amendment No.: 604-09', 'Toxicity grade or', 'irAE management with', 'Immune-related', 'conditions', 'Action taken to', 'corticosteroid and/or other', 'AEs', '(CTCAEv4.0)', 'pembrolizumab', 'therapies', 'Monitor and follow-up', 'All Other', 'Intolerable/', 'Persistent', 'Withhold', 'Based on severity of AE', 'Ensure adequate evaluation to confirm', 'immune-related', 'Grade 2', 'administer corticosteroids', 'etiology or exclude other causes', 'AEs', 'Grade 3', 'Withhold', 'or', 'discontinue', 'based on the type', 'of event. Events', 'that', 'require', 'discontinuation', 'include and not', 'limited', 'to:', 'Guillain-Barre', 'Syndrome,', 'encephalitis', 'Grade 4 or recurrent', 'Permanently', 'Grade 3', 'discontinue', 'Abbreviations: AE=adverse event, LL==lanine transaminase, AST=aspartate transaminase, CTCAEv4.0=Common Terminology Criteria for Adverse', 'Events', 'version', '4.0,', 'irAE=immune-related adverse event, IV=intravenous, T1DM=Type 1 diabetes mellitus', '1.', 'Withholding or permanently discontinuing pembrolizumab is at the discretion of the investigator or treating physician.', '2.', 'For subjects with Grade 3 or 4 immune-related endocrinopathy where withholding of pembrolizumab is required, pembrolizumab may be resumed when AE resolves', 'to Grade 2 and is controlled with hormonal replacement therapy or achieved metabolic control (in case of T1DM).', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '45', 'Protocol/Amendment No.: 604-09', 'Dose modification and toxicity management of infusion-reactions related to', 'pembrolizumab', 'Pembrolizumab may cause severe or life-threatening infusion-reactions including severe', 'hypersensitivity or anaphylaxis. Signs and symptoms usually develop during or shortly after', 'drug infusion and generally resolve completely within 24 hours of completion of infusion.', 'Dose modification and toxicity management guidelines for pembrolizumab associated', 'infusion reactions are provided in Table 5.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '46', 'Protocol/Amendment No.: 604-09', 'Table 5', 'Pembrolizumab Infusion Reaction Dose Modification and Treatment Guidelines', 'NCI CTCAE Grade', 'Treatment', 'Premedication at Subsequent Dosing', 'Grade 1', 'Increase monitoring of vital signs as medically indicated until the subject', 'None', 'Mild reaction; infusion', 'is deemed medically stable in the opinion of the investigator.', 'interruption not indicated;', 'intervention not indicated', 'Grade 2', 'Stop Infusion.', 'Subject may be premedicated 1.5 h', 'Requires therapy or infusion', 'Additional appropriate medical therapy may include but is not limited to:', '( 30 minutes) prior to infusion of', 'interruption but responds', 'IV fluids', 'pembrolizumab with:', 'promptly to symptomatic', 'Antihistamines', 'Diphenhydramine 50 mg po (or', 'treatment (eg, antihistamines,', 'NSAIDs', 'equivalent dose of antihistamine).', 'NSAIDs, narcotics, IV fluids);', 'Acetaminophen', 'Acetaminophen 500-1000 mg po (or', 'prophylactic medications', 'Narcotics', 'equivalent dose of analgesic).', 'indicated for 24 h', 'Increase monitoring of vital signs as medically indicated until the subject', 'is deemed medically stable in the opinion of the investigator.', 'If symptoms resolve within 1 hour of stopping drug infusion, the infusion', 'may be restarted at 50% of the original infusion rate (eg, from 100 mL/h', 'to 50 mL/h). Otherwise dosing will be held until symptoms resolve and', 'the subject should be premedicated for the next scheduled dose.', 'Subjects who develop Grade 2 toxicity despite adequate', 'premedication should be permanently discontinued from further', 'study drug treatment', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}